Real world study of apatinib mesylate combined with concurrent radiotherapy in the treatment of esophageal cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000039176

Enrollment

Unknown

Registered

2020-10-21

Start date

2020-11-01

Completion date

Unknown

Last updated

2021-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Single arm :apatinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years, male or female; 2. Patients with esophageal cancer confirmed by histology or cytology; 3. ECOG: 0-2; 4. At least 1 measurable lesion (meeting RECIST 1.1 criteria);

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients participating in other clinical studies; 3. Confirmed allergy to apatinib mesylate tablets and/or its excipients; 4. Except patients with contraindications to Apatinib; 5. The doctor thinks it is not suitable for inclusion; 6. Incomplete important imaging examinations and incomplete records of adverse reactions.

Design outcomes

Primary

Measure	Time frame
OS;	—

Secondary

Measure	Time frame
PFS;ORR;DCR;AE;	—

Countries

China

Contacts

Public ContactRuitai Fan

The First Affiliated Hospital of Zhengzhou University

fanrui@126.com86 13838083896

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026